Using macrophages to improve treatment for glioblastoma
Official title: Macrophage-based Therapy and Immune Checkpoint Blockade for Glioblastoma
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-10980510 · Data updated 2026-11-12
This study is looking at ways to help people with glioblastoma by changing certain immune cells in the body to fight the tumor better, hoping to make existing treatments work more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | December 1, 2022 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $368,288 |
| NIH project number | 5R01CA277966-03 |
| Project ID | NIH-10980510 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with glioblastoma who are seeking new treatment options.
✕Less likely to help
Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
What this research studies
This research focuses on glioblastoma, a highly aggressive brain tumor that is resistant to existing therapies. The approach involves reprogramming tumor-associated macrophages, which are immune cells that can either promote or suppress tumor growth. By converting these macrophages from a tumor-promoting state to a tumor-suppressing state, the research aims to enhance the effectiveness of immune checkpoint blockade therapies. The methodology includes screening small molecules that can stimulate macrophage activity to better target and eliminate glioma cells.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially improving survival rates and quality of life for patients.
How similar studies have gone: Other research has shown promise in reprogramming macrophages for cancer therapy, indicating that this approach could be a viable strategy.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Bao, Shideng — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Bao, Shideng
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.